Results 151 to 160 of about 26,737 (201)

Investigation of cyclic peptides as drug delivery systems for the delivery of the anti-tuberculosis drug pyrazinamide. [PDF]

Nanoscale Adv
Makiabadi B, Naderi F, Zakarianezhad M, Raessi A.   +3 more
europepmc   +1 more source

Cutaneous Tuberculosis Presenting as a Chronic Dermatologic Disorder. [PDF]

Case Rep Dermatol Med
Spina O, Fraimow H, Green J.
europepmc   +1 more source

Convolutional neural networks quantify antibiotic resistance in Mycobacterium tuberculosis with diagnostic grade accuracy and predict treatment response. [PDF]

Nat Commun
Kulkarni SG, Green AG, Mann BC, Malatesta S, Kulkarni-Goodwin S, Cesare N, Mulaudzi S, Rawoot N, MIC-ML Consortium, Warren RM, Jacobson KR, Farhat MR.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pyrazinamide

Reactions Weekly
  +7 more sources

Pyrazinamide

Reactions Weekly, 2015
  +5 more sources

Pyrazinamide

Reactions Weekly, 2012
  +5 more sources

PYRAZINAMIDE IN TUBERCULOSIS

The Lancet, 1981
L P, Ormerod, N, Horsfield
openaire   +2 more sources

Experience with Pyrazinamide

Diseases of the Chest, 1955
B P, POTTER, S F, CHANG
openaire   +2 more sources

Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing.

Antimicrobial Agents and Chemotherapy, 2021
Michael Ashton, Emile Bienvenu, Jesper Sundell   +2 more
exaly  

Pyrazinamide

Reactions Weekly, 2019
openaire   +2 more sources